The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Valeant Pharmaceutical’s offices in Montreal.
Valeant Pharmaceutical’s offices in Montreal.
(Ryan Remiorz/The Canadian Press)

It may be Valeant's turn to face the curse of the TSX

Mike Pearson, chairman and chief executive of Valeant Pharmaceuticals Inc., has a dream: Transform his company into a top five global pharmaceutical firm through internal growth and acquisitions.

His $46-billion offer for Allergan Inc. will bring the dream closer to reality, if it succeeds. But it comes with a potential downside – Valeant will be well on its way to becoming the top-weighted stock on the S&P/TSX composite index.